Alzheimer's Disease
The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer's disease.
Neurogen will integrate Tasso's needle-free blood collection devices into its home-based Alzheimer’s testing platform.
Atrio Health's Medicare Advantage plan members will have access to treatment services and care management for Alzheimer's disease and other forms of dementia.
The companies said that being listed as a provider on LillyDirect will expand patient access to Isaac Health care.
The funds will be used to increase the development of GAIA-based Alzheimer's disease drugs and widen the pipeline of blockbuster drug candidates.
M Ventures led the round with participation from Grey Sky Venture Partners, VI Partners AGG, Alpana Ventures and FYRFLY Ventures.
The Montreal-based company uses spectral retinal imaging technology and AI to deliver a cheaper alternative to early Alzheimer's disease detection.
As laid out in the 21st Century Cures Act, the Breakthrough Devices Program looks to streamline new medical technologies that offer improved treatment for serious diseases.